Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Lupin Ltd.
Change Company   
BSE Code 500257
ISIN Demat INE326A01037
Book Value 611.14
NSE Code LUPIN
Dividend Yield % 0.49
Market Cap 1124979.63
P/E 20.48
EPS 120.17
Face Value 2  
05-May-2026 Lupin gets USFDA’s nod for Glycerol Phenylbutyrat...
05-May-2026 Lupin informs about press release
22-Apr-2026 Lupin launches Dapagliflozin and Metformin Hydroc...
22-Apr-2026 Lupin inches up on launching Dapagliflozin and Me...
22-Apr-2026 Lupin informs about press release
20-Apr-2026 USFDA concludes inspection at Lupin’s USA manufac...
18-Apr-2026 Lupin incorporates wholly owned subsidiary in Tha...
18-Apr-2026 Lupin informs about inspection updates
11-Apr-2026 Lupin launches Dapagliflozin Tablets in US
11-Apr-2026 Lupin submits press release
08-Apr-2026 Lupin gets USFDA’s nod for Dapagliflozin and Metf...
08-Apr-2026 Lupin secures USFDA approval for Dapagliflozin ta...
08-Apr-2026 Lupin surges on securing USFDA approval for Dapag...
07-Apr-2026 Lupin gets Great Place To Work certification
07-Apr-2026 Lupin trades higher on the BSE
Page 1 of 6
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.